Last reviewed · How we verify
Experimental 1
At a glance
| Generic name | Experimental 1 |
|---|---|
| Sponsor | Eisai Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- The Impact of Equine-Assisted Therapy on Mental Health and Addictive Behaviors in Patients Receiving Addiction Treatment (NA)
- Conservative Treatment of Trigger Finger (NA)
- Safety Study of Intravenous Hydrogen-Oxygen Ultrafine Bubbles in Adults (PHASE1)
- A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Intense Strong (NA)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- Impact of Anatomy-Based Cochlear Implant Programming on Early Performance (NA)
- Effects of Positive Psychological Group Psychotherapy and Auricular Acupressure on Withdrawal Symptoms (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental 1 CI brief — competitive landscape report
- Experimental 1 updates RSS · CI watch RSS
- Eisai Inc. portfolio CI